Potential breakthrough for hard to treat cancers

Experts have developed a breakthrough small-molecule drug, a 'protein degrader'. This molecule, called ACBI3, could potentially lead to new therapies independent of KRAS mutation type, improving outcomes for all patients with cancers caused by KRAS mutations.